Bortezomib 1nM PU.1 GAPDH KMS12PE U266 U937 Supplemental Figure S1.

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.

Advertisements

Supplementary Table 1 A. B. CI simulations display synergism (CI 1) for the entire spectrum of effect levels (Fa) in the combination of NFV and BZ (right.

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

1.96E E E E E E+07 0E+0 1E+7 2E+7 3E+7 4E+7 5E+7 6E07 7E+7 8E+7 9E+7 hWASP1 Cell Growth Cell Number Days of Growth.

A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S

Supplemental Figure 1 A No. at risk T T T

Supplemental Figure 1: Chemical structures of fludioxonil and fenhexamid. FludioxonilFenhexamid.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Drug Reimbursement in Slovakia Role of the Slovak Myeloma Society Dr. Katarína Fedorová.

Supplementary Figure S1 Percentage of peaks from Trf1 +/+ p53 -/- -Cre vs Trf1  /  p53 -/- -Cre comparison that are located in non subtelomeric and subtelomeric.

Supplementary Figure 1. Supplementary Figure 2 Suppl. Fig. 1. The promoter of miR-155 encoding Bic gene contains two putative NF-  B binding sites.

12.1 Complementary and Supplementary Angles Homework: p689, #12-22 even.

Complimentary & Supplementary Angles. Vocabulary Words: Complementary Angles- two angles that come together to form a right angle (90ᵒ) Compliment- the.

Best 20 jobs jobs sites.

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

Figure 2. Effects of RUNX1 and PU. 1 siRNAs on CCR3 reporter activity

Course 3 Parallel Lines In the figure, line n || line m. Find the measure of the angle . 7 All obtuse angles in the figure are congruent m7 = 144°

ANP GAPDH CTL CTL+MB DB DB+MB CTL CTL+MB DB DB+MB

Supplemental Figure and Tables Legends

A 4 Band intensity (relative unit) MMP-9 MMP-2 B C 4 4

A B C Supplemental Figure S1 SET2 HEL BRD4 β-Actin SET2

Median Tumor Development Time

Multiple Myeloma: Diagnosis and Treatment

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

The Nurse View: Best Practices in Multiple Myeloma

Change in fluorescence / min

Angiogenesis Inhibitors

A B Supplementary Figure 3

SI Fig. 5 Thiosulfat, Acetate, NO3- Benzoat, NO3- DMSO, S0, Taurine,

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

Supplemental Figure S2: G2 arrest in MCF7-shPBK1 stable cell line

Supplementary Figure S2

Supplemental Figure 1A – I

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

500 nm WRITE VOLTAGE 0 V.

Supplemental Figure 1 1 mutation 2 mutations 3 mutations 4 mutations

Lutz et al, Neuropsychopharmacology

Supplementary Table 1.

Supplemental Figure 5 v A Idarubicin 100 nM Idarubicin 300 nM B C D

Supplementary Figure B. 50.

Supplemental Figure 1A Pt Pt Pre-treatment

Supplementary Figure S1

Supplemental Figure 1 – Age Distribution in the CAC Consortium

Supplementary Figure 1. A

Supplementary Figure 1. Structure of amlexanox

mRNA level as % relative to

Supplementary Figures

Abemaciclib (µM) LY (µM)

Supplementary Figure 1 ** ** _ _ + + a. b. ** ** _ _ + + c. n=3 RU486

Renal Function and Myeloma Therapeutics

Reh cells, 24 hours c-Myc Ac-p53 b-actin

Effect of RGS4 inhibitor, CCG50014 on the formalin-induced nociceptive responses in the RGS4-knockout mice A B Supplement. 1↑

Supplemental Figure 6 Effect of p. o

Volume 25, Issue 1, Pages e6 (January 2018)

A B C D Supplementary Figure S1 UMSCC1 Plateau: 24 hr Pre-Treatment

a b Supplementary Figure 1 Plasma Vosaroxin (ng/mL) Time (h)

Induction of apoptosis by nelfinavir and bortezomib

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

The development of proteasome inhibitors as anticancer drugs

Supplemental Figure 1 Cell proliferation (% of mock)

Treatment options for relapsed and refractory multiple myeloma

The Chemical Biology of Human Vitamins

Supplement Figure 1 Untreated Thermal IMDP CPLL Untreated Thermal IMDP

--- 6-months’ therapy months’ therapy Supplementary Figure 1.

Li and Xue, Supplemental Figure 1

A B Supplemental Fig. 1A-C Bap1Δ/Δ NMC MM 526 Bap1 Ub-H2A Nf2 Aldh1a2

Presentation transcript:

Bortezomib 1nM PU.1 GAPDH KMS12PE U266 U937 Supplemental Figure S1

A U266 Supplemental Figure S2 No treatment Lenalidomide 1µM PU.1-binding site Lenalidomide 1µM Supplemental Figure S2

B KMS12PE Supplemental Figure S2 No treatment Lenalidomide 1µM PU.1-binding site Lenalidomide 1µM Supplemental Figure S2

Supplementary Figure S3 DMSO Lenalidomide Pomalidomide RG108 1 µM Supplementary Figure S3

Supplemental Figure S4

A　 U266 CDKN1A　 CDKN1C　 SOCS1 SOCS3 Supplemental Figure S5

KMS12PE B　 CDKN1A　 CDKN1C　 SOCS1 SOCS3 Supplemental Figure S5